Attention Deficit Hyperactivity Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Attention Deficit Hyperactivity Disorder stocks.

Attention Deficit Hyperactivity Disorder Stocks Recent News

Date Stock Title
Jun 26 LLY 2 Reasons Why Eli Lilly's Stock Likely Hasn't Peaked
Jun 26 LLY Augustine Therapeutics raises €17M in series A first closing
Jun 25 CING Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
Jun 25 LLY Why Drugmaker Eli Lilly Is Partnering With ChatGPT Maker OpenAI
Jun 25 LLY AI Work Assistants Need a Lot of Handholding
Jun 25 LLY ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data
Jun 25 LLY Lilly gains approval of lebrikizumab in Canada for atopic dermatitis
Jun 25 LLY Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2
Jun 25 LLY Eli Lilly collaborates with OpenAI for medicines against drug-resistant bacteria
Jun 25 LLY Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
Jun 25 LLY Novo Nordisk Rises as Wegovy Is Approved in China
Jun 25 LLY From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces Hurdles
Jun 25 LLY Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
Jun 25 CING Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
Jun 25 LLY Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
Jun 25 NLSP Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
Jun 25 LLY Novo to spend $4B on US plant, adding to obesity drug production push
Jun 25 ZVRA Zevra Therapeutics Expands Executive Leadership Team
Jun 25 LLY Company News for Jun 25, 2024
Jun 24 LLY Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Attention Deficit Hyperactivity Disorder

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

Browse All Tags